Pro-Dex, Inc. (PDEX)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-05
$61.20-3.53%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-05
QuarterlyIQ Insights · PDEX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Management emphasizes continued sales growth, particularly shipments of the next-generation orthopedic handpiece to its largest customer.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 42% for the rest of the cohort, n=10089).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Management describes APM as an added revenue stream and machining-capacity resource, with its operations integrated into Pro-Dex.
Mr. Van Kirk concluded, “We are also pleased to be working with the Monogram and Zimmer Biomet teams and expect to ship validation units later this fiscal year.”
Stated in 1 of 3 supplied quarters. Management reported: “Mr. Van Kirk concluded, “We are also pleased to be working with the Monogram and Zimmer Biomet teams and expect to ship validation units later this fiscal year.””
“Mr. Van Kirk concluded, “We are also pleased to be working with the Monogram and Zimmer Biomet teams and expect to ship validation units later this fiscal year.””
Continue to grow revenue and operating income, driven by increased shipments of next generation orthopedic handpiece and acquisition synergies.
Complete integration of Advanced Precision Machining (APM) and leverage its revenue streams and machining capacity for growth.
Over the trailing year it converted 1.16x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 52% of the time over the next year (vs 44% for the rest of the cohort, n=3371).
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
16 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-05.